Antimycobacterial plant terpenoids

Planta Medica

Volumn 67, Issue 8, 2001, Pages 685-694

  Cantrell, C L ^a   Franzblau, S G ^b   Fischer, N H ^c  

^a NATIONAL CENTER FOR AGRICULTURAL UTILIZATION RESEARCH   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Antimycobacterial; Antituberculosis; Mycobacterium tuberculosis; Terpenoids; Tuberculostatic

Indexed keywords

1,10 EPOXYCOSTUNOLIDE; 1,10 EPOXYDIHYDROCOSTUNOLIDE; 1,10 EPOXYDIHYDROPARTHENOLIDE; 1,10 EPOXYPARTHENOLIDE; ALPHA CYCLOCOSTUNOLIDE; ALPHA SANTONIN; BETA CYCLOCOSTUNOLIDE; CITRONELLOL; COSTUNOLIDE; DAMSIN; DEHYDROCOSTUSLACTONE; DITERPENOID; ETHAMBUTOL; GERANIOL; ISONIAZID; MICHELIOLIDE; NEROL; PARTHENOLIDE; PUMILIN; PYRAZINAMIDE; REYNOSIN; RIFAMPICIN; SANTAMARINE; SESQUITERPENE DERIVATIVE; STREPTOMYCIN; TERPENOID; TRITERPENOID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALUZANIN C;

AMBROSIA CONFERTIFLORA; ANTIBACTERIAL ACTIVITY; ARTEMISIA RAMOSA; BERLANDIERA TEXANA; BIOASSAY; DRUG STRUCTURE; IN VITRO STUDY; MAGNOLIA GRANDIFLORA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLANT; REVIEW; SAUSSUREA LAPPA; TUBERCULOSIS; ZALUZANIA TRILOBA;

AMBROSIA CONFERTIFLORA; ARTEMISIA; BERLANDIERA TEXANA; MAGNOLIA GRANDIFLORA; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; SAUSSUREA; SAUSSUREA LAPPA; ZALUZANIA;

EID: 0034767432     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18365     Document Type: Review

References (47)

1. Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project
2. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic
3. New drugs for tuberculosis
4. Tuberculosis in the AIDS era
5. Drug-resistant tuberculosis: Review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease
6. Global trends in resistance to antituberculosis drugs
7. In vitro activity of rifabutin and rifampin against clinical isolates of Mycobacterium tuberculosis in Taiwan
8. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis
9. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: A pilot study
10. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis
11. The tolerability and therapeutic efficacy of rifabutin in the treatment of pulmonary tuberculosis
12. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: A new method of drug assessment
13. Evaluation of rifapentfne in long-term treatment regimens for tuberculosis in mice
14. Prospects for development of new antimycobacterfal drugs, with special reference to a new benzoxazinorifamycin, KRM-1648
15. Quinolones and multidrug-resistant tuberculosis
16. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis
17. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs
18. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens
19. Activity of moxifioxacin against mycobacteria
20. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis
21. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis
22. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model
23. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
24. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium
25. Antimycobacterial cycloartanes from Borrichia frutescens
26. Antimycobacterial activity of (E)-phytol and derivatives. A preliminary structure-activity study
27. Antimycobacterial evaluation of germacranolides
28. Spectral data of chemical modification products of costunolide
29. Antimycobacterial activities of dehydrocostus lactone and its oxidation products
30. Antimycobacterial eudesmanolides from Inula helenium and Rudbeckia subtomentosa
31. Norditerpenoids and diterpenoids from Salvia multicaulis with antituberculous activity
32. In vitro inhibition of mycobacteria by Rwandese medicinal plants
33. Diterpenes from the berries of Juniperus excelsa
34. A new antitubercular mulinane diterpenoid from Azorella madreporica Clos
35. Antimycobacterial ergosterol-5,8-endoperoxide from Ajuga remota
36. Antimycobacterial triterpenes from Melia volkensii
37. Antitubercular activity of pentacyclic triterpenoids from plants of Argentina and Chile
38. Oleanane triterpenes from Junellia tridens
39. New pseudoguianolides from Ambrosis confertiflora
40. Sesquiterpene lactones. Constituents of diploid and polyploid Ambrosia dumosa
41. Hydroxy-bis-dihydroencelin, a dimeric eudesmanolide and other eudesmanolides from Montanoa speciosa
42. Sesquiterpene lactones and other constituents from Rudbeckia mollis
43. The crystal structure of 6-epi-deacetyllaurenobiolide, a germacra-1(10),4-diene-12,8-alpha-olide from Montanoa grandiflora
44. Structure-activity relationships in fusidic acid-type antibiotics
45. Prediction of drug transport processes using simple parameters and PLS statistics. The use of ACD/logP and ACD/ChemSketch descriptors